Clinical Trial Update: Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating pharmacokinetics, pharmacodynamics, immunogenicity, and safety of rituximab compared to MabThera in rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)
• Rituximab (rituximab)

Snippet

Sponsor: Mabscale, LLC | Conditions: Rheumatoid Arthritis | Phase 1 | Status: ACTIVE_NOT_RECRUITING